Introduction —
This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Diagnosis and management of prostate cancer".)
International
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer, update (2024)
Canada
●Canadian Urological Association (CUA): Recommendations on prostate cancer screening and early diagnosis, update – Endorsement of the 2021 Cancer Care Ontario (CCO) guidelines on prostate multiparametric magnetic resonance imaging (2022)
●British Columbia Guidelines and Protocols Advisory Committee (GPAC): Prostate cancer – Part 1: Diagnosis and referral in primary care (2020)
●CCO: Position statement on prostate cancer screening using the prostate-specific antigen (PSA) test (2017)
●Canadian Task Force on Preventive Health Care (CTFPHC): Recommendations on screening for prostate cancer with the prostate-specific antigen test (2014)
United States
●American Academy of Family Physicians (AAFP): Clinical preventive service recommendation on prostate cancer – PSA-based prostate cancer screening in men aged 55-69
●National Cancer Institute (NCI): Prostate cancer – Health professional version
●Prostate Cancer Foundation (PCF): Screening guidelines for Black men in the United States (2024)
●American Urological Association (AUA)/Society of Urologic Oncology (SUO): Guideline on early detection of prostate cancer (2023)
●US Preventive Services Task Force (USPSTF): Final recommendation statement on prostate cancer – Screening (2018)
●American Cancer Society (ACS): Guideline for the early detection of prostate cancer, update (2010)
Europe
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer, update (2024)
●European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment, and follow-up – Prostate cancer (2020)
●ESMO: Consensus conference guidelines on prostate cancer, 2012 (published 2013)
United Kingdom
●Prostate Cancer UK: Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care – Report from a UK clinical consensus (2024)
India
●Chinese Society of Clinical Oncology (CSCO), Indian Society of Medical and Paediatric Oncology (ISMPO), Japanese Society of Medical Oncology (JSMO), Korean Society for Medical Oncology (KSMO), Malaysian Oncological Society (MOS), Singapore Society of Oncology (SSO), and Taiwan Oncology Society (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (2022)
Australia–New Zealand
●Royal Australian College of General Practitioners (RACGP): Guidelines for preventive activities in general practice – Prostate cancer, 10th edition (2024)
●Choosing Wisely Australia: Do not perform PSA testing for prostate cancer screening in men with no symptoms and whose life expectancy is less than 7 years (2022)
●Cancer Australia: Optimal care pathway for men with prostate cancer, second edition (2021)
●Cancer Council Australia (CCA) and Prostate Cancer Foundation of Australia (PCFA): Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer (2015)
●Australian National Health and Medical Research Council (NHMRC): Prostate-specific antigen (PSA) testing in asymptomatic men – Information for health practitioners (2014)
Japan
●[In English] Japanese Urological Association (JUA): Japanese clinical practice guidelines for prostate cancer, fourth edition (2023)
●[In English] Chinese Society of Clinical Oncology (CSCO), Indian Society of Medical and Paediatric Oncology (ISMPO), Japanese Society of Medical Oncology (JSMO), Korean Society for Medical Oncology (KSMO), Malaysian Oncological Society (MOS), Singapore Society of Oncology (SSO), and Taiwan Oncology Society (TOS): Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (2022)
●[In Japanese] Japanese Urological Association (JUA): Screening guideline for prostate cancer (2018)
●[In Japanese] Choosing Wisely Japan: PSA testing for prostate cancer – When men need it and when they do not (2016)
